Staar Surgical (NASDAQ:STAA) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 3 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 2 | 0 | 0 |
| 3M Ago | 2 | 0 | 1 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $47.57, along with a high estimate of $55.00 and a low estimate of $40.00. This upward trend is apparent, with the current average reflecting a 10.19% increase from the previous average price target of $43.17.
Understanding Analyst Ratings: A Comprehensive Breakdown
The perception of Staar Surgical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Ryan Zimmerman | BTIG | Announces | Buy | $46.00 | - |
| Jon Young | Canaccord Genuity | Lowers | Hold | $43.00 | $46.00 |
| Matt O'Brien | Piper Sandler | Raises | Neutral | $40.00 | $33.00 |
| Anthony Petrone | Mizuho | Raises | Buy | $55.00 | $53.00 |
| Anthony Petrone | Mizuho | Raises | Buy | $53.00 | $45.00 |
| Jon Young | Canaccord Genuity | Raises | Hold | $46.00 | $32.00 |
| Thomas Stephan | Stifel | Maintains | Buy | $50.00 | $50.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Staar Surgical. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Staar Surgical compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Staar Surgical's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Staar Surgical's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Staar Surgical analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
All You Need to Know About Staar Surgical
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
Financial Insights: Staar Surgical
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Staar Surgical's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 5.21%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Staar Surgical's net margin is impressive, surpassing industry averages. With a net margin of -4.32%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Staar Surgical's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.86%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Staar Surgical's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.68% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.09, Staar Surgical adopts a prudent financial strategy, indicating a balanced approach to debt management.
How Are Analyst Ratings Determined?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.